Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment.
Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment.
复制标题
DOI：
10.1016/j.coph.2018.05.013
复制
发表时间：
2018-10
影响因子：
4
通讯作者：
Mizrahi V
中科院分区：
文献类型：
--
作者：
Koch A;Cox H;Mizrahi V
在世界一些地区，结核病的管理因高度耐药性而变得复杂。分子诊断正越来越多地用于检测某些一线抗结核药物的耐药性。对其他药物的耐药性的基因型-表型关系是复杂的，使得通过分子方法进行DST具有挑战性。对耐多药结核病治疗管理采取个体化办法可能有助于最大限度地减少进一步耐药的发展。对耐多药结核病治疗管理采取个体化办法可能有助于最大限度地减少进一步耐药的发展。据估计，2016年的发病率为49万例，耐多药结核病（TB）对全球健康构成了重大挑战，而关键的一线抗结核药物对TB的疗效较差。治疗结果不佳，加上需要二线治疗的人与接受二线治疗的人之间的治疗差距越来越大，突出表明迫切需要采取新的方法来应对耐药结核病的祸害。在此背景下，在了解结核病耐药性和疾病发病机制的复杂生物学以及建立提供新药和药物组合的管道方面取得了重大进展。在这篇综述中，我们强调了耐药结核病的挑战以及利用新进展改善治疗结果的方法。
Management of tuberculosis is complicated by high levels of drug resistance in some regions of the world. Increasingly, molecular diagnostics are being used for resistance detection to certain first-line anti-TB drugs. Genotype-phenotype relationships for resistance to other drugs are complex making DST by molecular methods challenging. Individualized approaches to MDR-TB treatment management may help to minimize the development of further resistance. Individualized approaches to MDR-TB treatment management may help to minimize the development of further resistance. With an estimated incidence of 490 000 cases in 2016, multidrug resistant tuberculosis (TB), against which key first-line anti-tuberculars are less efficacious, presents major challenges for global health. Poor treatment outcomes coupled with a yawning treatment gap between those in need of second-line therapy and those who receive it, underscore the urgent need for new approaches to tackle the scourge of drug-resistant TB. Against this background, significant progress has been made in understanding the complex biology of TB drug resistance and disease pathogenesis, and in establishing a pipeline for delivering new drugs and drug combinations. In this review, we highlight the challenges of drug-resistant TB and the ways in which new advances could be harnessed to improve treatment outcomes.
登录
查看更多内容
影响因子：
13.6
作者：
Cokol M;Kuru N;Bicak E;Larkins-Ford J;Aldridge BB
通讯作者：
Aldridge BB
影响因子：
3.7
作者：
Coxon GD;Craig D;Corrales RM;Vialla E;Gannoun-Zaki L;Kremer L
通讯作者：
Kremer L
影响因子：
16.6
作者：
Bradley P;Gordon NC;Walker TM;Dunn L;Heys S;Huang B;Earle S;Pankhurst LJ;Anson L;de Cesare M;Piazza P;Votintseva AA;Golubchik T;Wilson DJ;Wyllie DH;Diel R;Niemann S;Feuerriegel S;Kohl TA;Ismail N;Omar SV;Smith EG;Buck D;McVean G;Walker AS;Peto TE;Crook DW;Iqbal Z
通讯作者：
Iqbal Z
DOI：
10.1016/j.tube.2014.02.005
发表时间：
2014-05
期刊：
Tuberculosis (Edinburgh, Scotland)
影响因子：
--
作者：
Coll F;Preston M;Guerra-Assunção JA;Hill-Cawthorn G;Harris D;Perdigão J;Viveiros M;Portugal I;Drobniewski F;Gagneux S;Glynn JR;Pain A;Parkhill J;McNerney R;Martin N;Clark TG
通讯作者：
Clark TG
DOI：
10.1016/s2213-2600(14)70031-1
发表时间：
2014-04
期刊：
The Lancet. Respiratory medicine
影响因子：
--
作者：
Dheda K;Gumbo T;Gandhi NR;Murray M;Theron G;Udwadia Z;Migliori GB;Warren R
通讯作者：
Warren R